Life Science Intelligence Blog

According to recently shared research from CB Insights, there are over 30 healthcare startups valued at over $1B. The majority of these “unicorns” are developing solutions for the rapidly growing digital healthcare market. Artificial intelligence (AI), cloud-based solutions, big data, and other technological innovations are all being explored and implemented in new ways to improve the healthcare industry.

Early-stage medtech companies Quantason, CivaTech Oncology, Navigation Sciences, MagForce and ChemoTech are going after Cancer in big ways.  

Identifying cancer and treating it in its earliest stages is one of the greatest challenges facing our healthcare system. Early detection and treatment of cancer is linked to the best clinical outcomes in terms of overall survival and treatment success. To that end, many pharmaceutical, diagnostic, and medical device developers are committed to addressing the global burden of cancer. Recent statistics from the International Agency for Research on Cancer estimated that there 17 million incident cases of cancer and 9.5 million deaths attributable to cancer globally in 2018. Global forecasts suggest that the burden of cancer will only grow despite current efforts to address the disease. There is still much work to be done if we are to successfully “beat cancer”. While pharmaceuticals, or chemotherapy, often come to mind when people think of how cancer is treated, the reality is that cancer treatment is a complex process that integrates multiple diagnostics and therapeutic options.

Traditional medtech strategics Johnson & Johnson, Medtronic, Abbott, and now the likes of tech giants Apple, Google, and Amazon are all aggressively investing in digital health, smartphone applications, wearable devices, and pursuing other strategies.

Select innovators Ossio, Greenbone, Embody, Biorez, Carmell Therapeutics, Nanochon, ZKR Ortho, HAPPE Spine will be in the spotlight (and no doubt catching attention from investors and major strategics) at the Emerging Medtech Summit.

Heart failure and CHF are some of the most costly chronic conditions to treat due to the severity and progression of the disease. A review published in the American Journal of Medicine estimates that the annual cost of treating heart failure among Medicaid beneficiaries ranges from $29,271 to $51,937. Despite advances in cardiovascular disease management, improvements in the mortality rates of heart failure patients has lagged behind other chronic conditions. In order to address the burden that heart failure poses, next-generation solutions are essential.

Technological advances in neurostimulation products are helping more people regain control of their lives from debilitating neurological disorders. Growth in the multibillion dollar neurostimulation market is showing no signs of slowing down as these devices become more accessible to the millions of people affected by neurological disorders. Significant fundraising and investment in the R&D of novel neurostimulation technologies lends additional evidence to the massive growth that this market is capable of in the future. A severely underserved population of patients with a myriad of difficult to treat disorders means there is an urgent need for novel solutions that provide therapeutic relief for chronic neurological conditions.

The Emerging Medtech Summit 2020 will spotlight Sixty (60) of the hottest emerging medtech companies, many of which are raising capital, ripe for M&A, or already planning for an IPO or exit.